

Esmo 2022 preview - duelling datasets



Jacob Plieth

[Most late-breaker titles](#) for Esmo are now disclosed, and in terms of biotech catalysts the upcoming meeting's regular abstracts cannot be ignored either. In some cases the latter will allow a handy comparison to be made against the former. For instance, investors in Springworks, whose nirogacestat features in a late-breaker, will pay attention to Ayala's rival gamma-secretase inhibitor AL102, which has a regular Esmo abstract; both datasets concern the niche area of desmoid tumours, but Ayala is worth just \$20m, barely 2% of Springworks' market cap. Data on Daiichi Sankyo's B7H3-targeted DS-7300, which uses the same ADC technology as Enhertu, will be of interest to Macrogenics investors, while first-in-human results are due from studies of Deciphera's DCC-3116 and Regeneron's ubamatamab. An update to results at Esmo 2021 concerns Amgen's Lumakras in combination with Vectibix in colorectal cancer, while an earlier-stage Kras G12C inhibitor, Roche's GDC-6036, has phase 1 data. The main course at Esmo for Kras watchers is Mirati's adagrasib late-breaker, also in colorectal cancer. Indeed, Kras is something of an Esmo theme, with sessions including two satellite and several special symposia.

Selected Esmo 2022 abstracts

Project (company)	Study (use)	Note	Abstract
Lumakras + Vectibix (Amgen)	Codebreak-101 (Kras G12C+ve colorectal cancer)	Had data at Esmo 2021, cf LBA24 on Mirati's adagrasib	3150
GDC-6036 (Roche)	Ph 1 (Kras G12C+ve solid tumours)	Field getting crowded	459MO
CART-ddBCMA (Arcellx)	Interim ph1 (multiple myeloma)	Data at Asco 2022	6200
AL102 (Ayala, ex-Bristol Myers Squibb)	Ringside (desmoid tumours)	Gamma secretase inhibitor, cf LBA2 on Springworks' nirogacestat	1488MO
DS-7300 (Daiichi Sankyo)	Ph1/2 (solid tumours)	Anti-B7H3, cites durable responses, cf Macrogenics MGC018	4530
DCC-3116 (Deciphera)	First in human, incl MAPk combo (solid tumours)	ULK1/2 inhibitor (data at AACR 2022)	4500
Ubamatamab (REGN4018; Regeneron)	Ph1/2 monotherapy cohort (ovarian cancer)	Anti-Muc16 T-cell engager	523MO
Giredestrant (Roche)	AcelERA (2L HR+/Her2- breast cancer)	Failed Serd study	211MO
Amcenestrant (Sanofi)	Ameera-3 (2L HR+/Her2- breast cancer)	Failed study, Serd recently discontinued by Sanofi	212MO

Source: Esmo website, company statements & clinicaltrials.gov.

[More from Evaluate Vantage](#)

Evaluate HQ
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas
[+1-617-573-9450](tel:+1-617-573-9450)

Evaluate APAC
[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

© Copyright 2022 Evaluate Ltd.